Astria Therapeutics (Astria Therapeutics) 5-Year ROIIC % : -644.49% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Astria Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -644.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Astria Therapeutics's 5-Year ROIIC % or its related term are showing as below:

ATXS's 5-Year ROIIC % is ranked worse than
90.36% of 1380 companies
in the Biotechnology industry
Industry Median: -19.115 vs ATXS: -644.49

Astria Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for Astria Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics 5-Year ROIIC % Chart

Astria Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

5-Year ROIIC %

Get a 7-Day Free Trial

-160.68

536.80

-215.37

-874.18

-644.49

Astria Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
5-Year ROIIC %	Get a 7-Day Free Trial															-874.18	-	-	-	-644.49

Competitive Comparison of Astria Therapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, Astria Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astria Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's 5-Year ROIIC % falls into.

Astria Therapeutics 5-Year ROIIC % Calculation

Astria Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -67.831 (Dec. 2023) - -26.371 (Dec. 2018) )	/	( 8.1 (Dec. 2023) - 1.667 (Dec. 2018) )
	=	-41.46	/	6.433
	=	-644.49%^***

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Astria Therapeutics (NAS:ATXS) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Astria Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Astria Therapeutics (Astria Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 1400, Boston, MA, USA, 02109

Website

https://www.astriatx.com

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews	officer: Chief Business Officer	C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Christopher Morabito	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Andrew Komjathy	officer: Chief Commercial Officer	CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols	officer: Chief Scientific Officer	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp	director, 10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck	director	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole	director	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger	officer: Secretary and General Counsel	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142